| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
RY796 targets voltage-gated potassium channels, specifically the KV2.1 and KV2.2 subtypes, acting as a potent and selective inhibitor. It also shows activity against casein kinase 2 (CK2) in some reports, but the primary and more consistently reported target is the KV2 channel. By inhibiting these channels, RY796 modulates neuronal excitability and neurotransmitter release.
|
|---|---|
| ln Vitro |
RY796 is a potent inhibitor of KV2.1 and KV2.2 with IC50 values of 0.25 μM and 0.09 μM, respectively. It has demonstrated analgesic activity in preclinical studies. The compound inhibits Kv2.x channels and enhances glucose-stimulated insulin secretion (GSIS) in isolated wild-type mouse and human islets, indicating additional metabolic effects.
|
| ln Vivo |
RY796 inhibits Kv2.x channels and enhances glucose-stimulated insulin secretion (GSIS) in isolated wild-type mouse and human islets. It has demonstrated analgesic activity in preclinical in vivo models, suggesting efficacy in pain management. The compound is used in neurological research to study channel function and pain pathways.
|
| Enzyme Assay |
The in vitro activity of RY796 is assessed using electrophysiological techniques, such as patch-clamp recording, on cells expressing KV2.1 or KV2.2 channels. The compound is applied at various concentrations, and the inhibition of potassium currents is measured to determine IC50 values. Selectivity against other KV channel subtypes is also evaluated.
|
| Cell Assay |
Cell-based assays are used to evaluate RY796's functional effects. For example, its ability to enhance glucose-stimulated insulin secretion is assessed using isolated pancreatic islets from wild-type mice or humans. The islets are treated with RY796, and insulin release is measured by ELISA. Additionally, neuronal cell lines can be used to study channel modulation.
|
| Animal Protocol |
RY796 has been evaluated in animal models for analgesic activity, typically administered systemically to rodents. Pain responses are measured using standard assays such as the tail-flick or formalin test. Its effects on glucose homeostasis can be studied in mouse models by monitoring blood glucose and insulin levels after oral or intraperitoneal administration.
|
| ADME/Pharmacokinetics |
RY796 has a molecular weight of 353.46 and a molecular formula of C21H27N3O2. The IUPAC name is 2-(dimethylamino)-5-(2-methylpropanoylamino)-N-[(1R)-1-phenylethyl]benzamide. It is soluble in DMSO (80 mg/mL) and should be stored desiccated at -20°C for long-term stability. Purity is typically ≥95% by HPLC.
|
| Toxicity/Toxicokinetics |
RY796 is a research compound and its full toxicological profile is not detailed in the literature. In preclinical studies, it has been used at various doses without significant adverse effects reported. As a potassium channel modulator, it may affect cardiac and neuronal function at high doses. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
RY796 (CAS#: 1393441-53-6) is a selective voltage-gated potassium (KV2) channel inhibitor with IC50 values of 0.25 μM (KV2.1) and 0.09 μM (KV2.2). It has demonstrated analgesic activity and is used in neurological research. Some sources also report it as a CK2 inhibitor. The compound is a valuable research tool for studying KV2 channel function, pain mechanisms, and pancreatic islet biology. It is intended for research use only and not for therapeutic applications.
|
| Molecular Formula |
C21H27N3O2
|
|---|---|
| Molecular Weight |
353.457985162735
|
| Exact Mass |
353.21
|
| CAS # |
1393441-53-6
|
| PubChem CID |
76850157
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(C1C=C(C=CC=1N(C)C)NC(C(C)C)=O)N[C@H](C)C1C=CC=CC=1
|
| InChi Key |
LDXZFQWWXMRMAS-OAHLLOKOSA-N
|
| InChi Code |
InChI=1S/C21H27N3O2/c1-14(2)20(25)23-17-11-12-19(24(4)5)18(13-17)21(26)22-15(3)16-9-7-6-8-10-16/h6-15H,1-5H3,(H,22,26)(H,23,25)/t15-/m1/s1
|
| Chemical Name |
2-(dimethylamino)-5-(2-methylpropanoylamino)-N-[(1R)-1-phenylethyl]benzamide
|
| Synonyms |
RY-796; RY 796; RY796
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8292 mL | 14.1459 mL | 28.2917 mL | |
| 5 mM | 0.5658 mL | 2.8292 mL | 5.6583 mL | |
| 10 mM | 0.2829 mL | 1.4146 mL | 2.8292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
